-
Cubans bid farewell to revolution hero Valdes
-
Morocco squad 'supporting' Hakimi despite impending rape trial
-
Ronaldo delights in silencing 'attacks' after making World Cup history
-
Airbus to inspect 16 A380s after cracks found on plane wings
-
'Paris in this heat is awful': Tourists change plans as sites close early
-
Bolivian government says cleared all protest roadblocks
-
'I'm back': Ronaldo scores at sixth World Cup as Portugal run riot
-
France has hottest-ever day as 'unbearable' heatwave keeps scorching Europe
-
US TV news host begs for info after kidnap note says mother is dead
-
Ronaldo double fires Portugal, England eye last 32
-
Ronaldo scores at sixth World Cup as Portugal run riot
-
Hollywood powerhouses bring AI fight to Europe
-
Portugal's Ronaldo first man to score at six World Cups
-
What is driving Europe's heatwave?
-
Rubio says US will not accept Iranian tolls on Hormuz
-
Spain's Oyarzabal happy to play through pain at World Cup
-
Marco Rubio in Gulf to reassure allies hit hard by Mideast war
-
US Supreme Court rules against man whose dreadlocks were cut off in prison
-
American Michele Kang agrees deal to buy French club Lyon
-
UN to begin evacuating stranded Mideast sailors after US-Iran talks
-
French farmers suffer arid crops, heat-stricken animals
-
Tech drags down world stocks, oil dips on supply hopes
-
Scorching heat shuts Paris landmarks early as France swelters
-
Shootout traps tourists at Rio sunrise lookout
-
Ipswich hire Gary O'Neil as manager
-
Heatwave sparks health warnings across Europe
-
Lake wins Wales captaincy race ahead of Morgan
-
Hundreds of schools close as UK braces for record-breaking heatwave
-
Tech names drag down world stocks, oil dips on supply hopes
-
Starmer vows 'orderly' transition as Labour MPs mull bid to be PM
-
Reports of Dupont inclusion in France squad 'bordering on annoying' says Galthie
-
ACTIVIST SHAREHOLDER FILES SCHEDULE 13D IN EQUUS TOTAL RETURN, INC.
-
England coach McCullum denies rift with 'good friend' Stokes
-
Europe: the world's fastest-warming continent
-
Taliban officials hold EU migration talks in Brussels
-
Gennaro Gattuso returns to coaching with Lazio after Italy debacle
-
Kenya halts US Ebola facility: health minister tells court
-
Why the heat is wreaking havoc on Europe's trains
-
Zelensky to skip key Ukraine conference in Poland over WWII row
-
Seoul leads rout for tech shares as oil prices dip
-
Europe heatwave closes schools, threatens health
-
India monsoon sweeps north but brings less rain than usual
-
Germany eyes longer working lives in pension reform plan
-
UK and markets await Burnham's economic plans
-
Iran says won't allow UN inspectors at bombed nuclear sites
-
Heineken names new CEO after predecessor's shock departure
-
Banned Vondrousova insists she has 'never doped'
-
Schools plan to close as UK braces for record-breaking heatwave
-
UN chief urges AI firms to 'come clean' over environmental footprint
-
India startup head Kunal Shah appointed as new WhatsApp boss
CELFULL Unveils Celfavor NADH Microcapsules: A Breakthrough in Stability That Reshapes the Anti-Aging Industry
CORAL SPRINGS, FL / ACCESS Newswire / July 4, 2025 / CELFULL, a biotechnology company with over 25 years of expertise in anti-aging science, has announced a major breakthrough in longevity innovation: the global launch of Celfavor® NADH Microcapsules, a patented delivery system that resolves the century-long challenge of NADH instability.

Journal papers related to NADH
This revolutionary technology-protected by seven international invention patents across the U.S., China, Japan, Canada, and South Korea-delivers unprecedented improvements in stability, bioavailability, and targeted delivery, marking a new era in anti-aging therapeutics known as the "Microcapsule Age." To accelerate research across the globe, CELFULL has also launched its Global Research Sharing Program, offering free access to the Celfavor® NADH raw material to scientific institutions worldwide.

Celfavor®NADH The only effective NADH - Celfavor ® NADH
"The discovery of the therapeutic effect of stabilized NADH is more important to humankind than the discovery of antibiotics." noted Nobel Laureate Sir John Eccles, underscoring the importance of this innovation.
NADH stands for "nicotinamide adenine dinucleotide (NAD) + hydrogen (H), often dubbed the "King of Anti-Aging Molecules," plays a central role in mitochondrial energy production, antioxidant defense, and the activation of longevity proteins. However, its inherent instability-sensitive to heat, light, oxygen, and stomach acid-has severely limited its clinical applications. Conventional NADH degrades by over 70% in one month at room temperature and must be stored at -20°C, making practical use difficult.

7 patents have been certified
CELFULL's research team, led by its AI-powered Multi-Target Anti-Aging Institute, spent over a decade solving this problem. The result: Celfavor® NADH Microcapsules, a proprietary technology featuring 250-350μm microcapsules that protect NADH with a multi-core soluble shell made from food-grade materials.
In stability tests simulating harsh conditions (40°C / 75% RH), traditional NADH retained only 3.5% of its activity after six months. By contrast, Celfavor® NADH maintained 98.3% activity-demonstrating over 6x shelf-life extension, even without refrigeration or light shielding.

The stability of Celfavor® NADH microspheres
The Celfavor® NADH Microcapsule system delivers innovation across four dimensions:
1. Enhanced Stability: Microcapsules shield NADH from air, moisture, light, and stomach acid, preserving its full potency in gastrointestinal conditions for up to 4 hours.
2. Targeted Release: Using AI-optimized wall material, the system enables "zero release in the stomach and sustained release in the intestine." Simulated intestinal studies show 24-hour continuous release, extending absorption time by 5-8x.
3. Superior Bioavailability: In human trials, a daily dose of 40mg led to a 98% increase in blood NAD⁺ levels, a 3.2x improvement over regular NADH. Performance also surpassed other NAD⁺ precursors like NMN and NR.
4. Formulation Flexibility: Unlike unstable NADH, Celfavor® NADH can be safely co-formulated with vitamins, coenzymes, or peptides in single or multi-ingredient capsules.

Celfavor ® NADH microsphere advanced technology surpasses others
Celfavor® NADH Microcapsules have been granted seven invention patents and passed all 12 safety evaluations, including cytotoxicity and long-term toxicity tests. It is currently the only NADH raw material globally to pass full-spectrum safety certification.

The only globally certified raw material for toxicology and safety experiments
"We are not just creating better products-we are building a platform for the future of longevity," said Dr. Juliane Hitzel, CEO of CELFULL. "With this microcapsule technology, we're launching new delivery systems for vitamins, peptides, and more. And by sharing our raw materials with global researchers, we're fostering a collaborative ecosystem that accelerates anti-aging science."
From solving the NADH stability problem to advancing intelligent delivery systems, CELFULL's innovation signals a major milestone in human longevity science. As the Celfavor® NADH Microcapsule technology rolls out globally, the anti-aging industry enters a new chapter-one defined by precision, efficiency, and collaboration.
For business cooperation or research partnerships, please contact:
[email protected] | www.celfull.com
Email: [email protected]
Website: www.celfull.com
SOURCE: CELFULL
View the original press release on ACCESS Newswire
N.Mitchell--AT